Exagen (XGN)
(Delayed Data from NSDQ)
$2.65 USD
-0.05 (-1.85%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $2.77 +0.12 (4.53%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.65 USD
-0.05 (-1.85%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $2.77 +0.12 (4.53%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
Zacks News
Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Exagen (XGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Exagen (XGN) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
Exagen (XGN) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Exagen (XGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Fast-paced Momentum Stock Exagen (XGN) Is Still Trading at a Bargain
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exagen (XGN) delivered earnings and revenue surprises of 55.56% and 14.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Time to Play 5 Top-Ranked Stocks With Rising P/E?
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Exagen (XGN), Health Catalyst (HCAT), CLEAR Secure (YOU) and Applied DNA Sciences (APDN).
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exagen (XGN) delivered earnings and revenue surprises of 52.50% and 9.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix (QTRX) delivered earnings and revenue surprises of 21.21% and 1.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exagen Inc. (XGN) delivered earnings and revenue surprises of 24.39% and 20.40%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Cresco Labs Inc. (CRLBF) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of 150% and 3.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of -76.47% and 12.44%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Despite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain Stock
by Zacks Equity Research
Exagen Inc. (XGN) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exagen Inc. (XGN) delivered earnings and revenue surprises of 41.67% and 28.92%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exagen Inc. (XGN) delivered earnings and revenue surprises of 15.38% and 18.21%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Veru Inc. (VERU) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veru Inc. (VERU) delivered earnings and revenue surprises of -33.33% and 66.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 55.56% and 11.77%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exagen Inc. (XGN) delivered earnings and revenue surprises of 18.31% and 48.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
High Tide Inc. (HITI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
High Tide Inc. (HITI) delivered earnings and revenue surprises of 28.57% and 6.13%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exagen Inc. (XGN) delivered earnings and revenue surprises of 38.16% and 61.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Warby Parker Inc. (WRBY) Q3 Earnings Match Estimates
by Zacks Equity Research
Warby Parker Inc. (WRBY) delivered earnings and revenue surprises of 0% and 2.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Quanterix Corporation (QTRX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 4.76% and 18.11%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 14.86% and 29.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Exagen Inc. (XGN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Exagen Inc. (XGN) delivered earnings and revenue surprises of -41.82% and 25.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exagen Inc. (XGN) delivered earnings and revenue surprises of -1.69% and 2.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?